TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35727095
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily for 4 weeks followed by 40 mg for 8 weeks
Study: 35727095
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg for 4 weeks followed by 20 mg for 8 weeks
Study: 34314906
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg intravenous granisetron
Study: 34314906
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml normal saline (placebo)
Study: 35246123
Drug: Biologics (mepolizumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics (mepolizumab, benralizumab, dupilumab)
Study: 34528335
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) referral volume from PSCs
Study: 33419469
Drug: New experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: New experimental therapy
Study: 32743954
Drug: Prucalopride 4
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prucalopride 4 mg daily
Study: 32162274
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate 250 mg BID
Study: 32162274
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg QD
Study: 36170688
Drug: Low-dose glucocorticoids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucocorticoids (dexamethasone 8 mg)
Study: 32809976
Drug: HRZE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRZE treatment
Study: 32809976
Drug: Ineffective therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineffective therapy
Study: 32748293
Drug: Clazosentan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (20 mg/h i.v. for 3 h)
Study: 32748293
Drug: Clazosentan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (60 mg/h i.v. for 3 h)
Study: 32748293
Drug: Moxifloxacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (single oral dose of 400 mg)
Study: 33957025
Drug: 1.0% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% hydrogen peroxide mouthwash and 0.5% hydrogen peroxide nasal spray for 7 days
Study: 35848045
Drug: Robot‐assisted mirror
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot‐assisted mirror therapy (RMT)
Study: 35848045
Drug: Standard mirror
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard mirror therapy (MT)
Study: 33676601
Drug: Chemotherapy (capecitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine)
Study: 34618367
Drug: Topical Cyperus
Normalized name: Cyperus rotundus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cyperus rotundus essential oil (CREO)
Study: 34618367
Drug: Placebo (cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cold cream)
Study: 33129289
Drug: Prednisolone 10
Normalized name: prednisolone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 10 mg
Study: 34316231
Drug: Intrauterine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine administration of 500 IU hCG (0.5 ml) before IUI
Study: 34316231
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 0.5 ml of normal saline before IUI
Study: 34414368
Drug: QazCovid-in® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: QazCovid-in® vaccine (5 μg each, two doses, administered intramuscularly, 21 days apart)
Study: 34414368
Drug: QazCovid-in® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: QazCovid-in® vaccine (one dose on day 1)
Study: 34414368
Drug: QazCovid-in® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: QazCovid-in® vaccine (two doses on day 1 and 21)
Study: 34414368
Drug: QazCovid-in® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: QazCovid-in® vaccine (two doses on day 1 and 21) for subjects aged ≥50 years
Study: 34414368
Drug: QazCovid-in® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: QazCovid-in® vaccine (one dose on day 1) for subjects aged ≥50 years
Study: 34414368
Drug: QazCovid-in® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: QazCovid-in® vaccine (after second dose)
Study: 33097947
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2000 mg/d DHA + 400 mg/d EPA)
Study: 33097947
Drug: Curcumin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (160 mg/d)
Study: 33737025
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg twice daily for extended thromboprophylaxis (ETP) after radical cystectomy
Study: 33114457
Drug: Family-based mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based mental health program, eight sessions, details on dosage and duration not specified.
Study: 33324593
Drug: Isoniazid exposure
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid exposure during tuberculosis preventive treatment (IPT)
Study: 33324593
Drug: Multi-B vitamin
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multi-B vitamin therapy (containing 300 mg nicotinamide daily) and isoniazid cessation
Study: 33324593
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of niacin metabolites (1-methylnicotinamide and l-methyl-2-pyridone-5-carboxamide) in urine
Study: 34145993
Drug: Levosimendan (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.2 μg/kg/min for 24 hours)
Study: 34406254
Drug: Pulsed Electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Electromagnetic Field (PEMF) therapy applied at 50 Hz, 25 G intensity, 20 min/session
Study: 32792250
Drug: IIV by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV by MNP administered by healthcare worker (HCW)
Study: 32792250
Drug: IIV by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV by MNP self‐administered by study participants
Study: 32792250
Drug: IIV by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV by intramuscular (IM) injection administered by HCW
Study: 32792250
Drug: Placebo by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by MNP administered by HCW
Study: 33870760
Drug: Topical skin
Normalized name: Betadine 7.5% Topical Skin Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical skin adhesive (TSA)
Study: 34292180
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg preoperatively + 40 mg/day postoperatively (80/40-mg group)
Study: 34292180
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day postoperatively (20-mg group)
Study: 34292180
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day postoperatively (40-mg group)
Study: 32415684
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg single dose
Study: 32415684
Drug: Selexipag 200
Normalized name: SELEXIPAG 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag 200 μg twice daily
Study: 34313812
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 10 mg weekly
Study: 35355656
Drug: Norepinephrine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (6 μg/mL) infused at 60 mL/h
Study: 35355656
Drug: Phenylephrine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (75 μg/mL) infused at 60 mL/h
Study: 35254839
Drug: IV nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV nicotine (0.0125, 0.025, 0.05, 0.1, or 0.2 mg/70 kg)
Study: 35254839
Drug: IV nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV nicotine (0.1 mg)
Study: 32275361
Drug: Tiaoshen acupuncture
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaoshen acupuncture (acupuncture for regulating the spirit) applied in the observation group, including additional acupoints Baihui (GV 20), Shenting (GV 24), and Benshen (GB 13). Treatment given once a day, 6 times a week, for 3 weeks.
Study: 32275361
Drug: Conventional acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupuncture at lower limbs' acupoints (Zusanli (ST 36), Yanglingquan (GB 34), and Xuanzhong (GB 39)) applied in the control group. Treatment given once a day, 6 times a week, for 3 weeks.
Study: 33951339
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg CBD twice daily with 200 mg caffeine on day 26
Study: 33951339
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 200 mg caffeine on day 1
Study: 35633196
Drug: Acetaminophen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (20 mg/kg PO)
Study: 35633196
Drug: Acetaminophen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (30 mg/kg PO)
Study: 35633196
Drug: Phenylbutazone (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (2.2 mg/kg PO)
Study: 35633196
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (C)
Study: 32907603
Drug: Multicomponent implementation
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent implementation strategy including training and point-of-service tools (e.g., desktop chart with prompts for offering brief counseling)
Study: 32771996
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ticagrelor for 3 months
Study: 32771996
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel for 3 months
Study: 32771996
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without HPR continued on aspirin and clopidogrel
Study: 34797205
Drug: Real GSM
Normalized name: carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real GSM 900 MHz mobile phone exposure (pulse modulated at 217 Hz, mean power of 250 mW and 2 W peak, with a maximum specific absorption rate of 0.70 W/kg on 1 g tissue)
Study: 35843242
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care with salvage chemotherapy followed by autologous stem cell transplantation
Study: 36286254
Drug: Haloperidol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2.5 mg 3 times daily plus 2.5 mg as needed, max 20 mg daily)
Study: 35815359
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICSs)
Study: 34599031
Drug: Seviprotimut-L 40
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seviprotimut-L 40 mcg
Study: 37942666
Drug: Titanium-zirconium (TiZr)
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium-zirconium (TiZr) implants
Study: 38335499
Drug: Prednisone 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 0.75 mg/kg/d
Study: 35786344
Drug: Nano-curcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-curcumin (80 mg/day)
Study: 34635802
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg/day
Study: 32980280
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication (paracetamol, NSAID, opioids, neuropathic pain medication)
Study: 32980280
Drug: Neuropathic pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropathic pain medication
Study: 33526485
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate (2.4 mg/kg)
Study: 32293286
Drug: Inverse Probability
Normalized name: Inversedine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inverse Probability of Treatment Weighting (IPTW)
Study: 34813414
Drug: Prostacyclin 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin 1 ng/kg/min infusion for 72 hours
Study: 32035624
Drug: Preflushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preflushing with saline at high speed (10 ml/s) before connecting to the catheter
Study: 32035624
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection procedure (control group)
Study: 34816795
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral amoxicillin (dose-by-age) given three times daily for 7 days
Study: 34816795
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral amoxicillin (dose-by-age) given three times daily for 7 days
Study: 34816795
Drug: Immediate topical
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate topical ciprofloxacin (0.3%) solution, four drops given three times daily for 7 days
Study: 34192431
Drug: Daratumumab group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab group (subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles)
Study: 36143902
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment with nitinol stents (NS)
Study: 33225990
Drug: Prone positioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prone positioning therapy throughout the day as long as possible, with breaks according to tolerance.
Study: 33225990
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group allowed prone positioning as a rescue therapy.
Study: 34001215
Drug: Camostat mesylate
Normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesylate (200 mg per capsule, one capsule taken each in the morning, afternoon, and evening on days 1-7)